Category: Intellectual property
-
Collapsed Microbiome Biotech Sells Off Assets
A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program.
-
Vaccine Shown to Protect Against Multiple Hospital Pathogens
Research with lab mice shows an experimental vaccine stimulates the body’s basic immune system to protect against a range of pathogens associated with hospital infections.
-
Cardiac Tech Start-Up Partners with Mayo Clinic
A new company developing digital cardiac diagnostics is collaborating with the Mayo Clinic on early detection of coronary artery disease, a key trigger of heart attacks.
-
University Start-Up Developing Inhaled Gene Therapies
A new company spun-off from a university lab consortium is advancing gene therapies delivered through the lungs to treat rare inherited respiratory diseases.
-
Venture Firm, Cancer Center Start Antibody Biotech Company
A company formed by M.D. Anderson Cancer Center and Panacea Venture plans to develop synthetic antibodies as treatments addressing new cancer targets.
-
Company Gains Ultrasound-Linked Drug Capsule Technology
A company developing a drug delivery process with treatments activated by ultrasound received an option to license a key technology from its founders’ university labs.
-
Companies to Assess Ovarian Health Biotech Drug
A women’s health biotechnology company is partnering with a Brazilian drug maker to evaluate a precision target and treatment for ovarian health disorders.
-
Bio-Friendly Plant Nutrient Delivery Patent Awarded
A process for delivering nutrients for crop growth that its developers say is more sustainable than most fertilizer methods today received a U.S. patent.
-
Patent Issued for Synthetic Peptide Chain Techniques
A new U.S. patent, licensed to a start-up biotechnology company, describes processes for linking together chains of synthetic peptides into therapeutic proteins.
-
Pharma Company Gains Precise Gene Edits in $2B Biotech Deal
A global drug maker is acquiring access to a biotechnology company’s precise genome editing techniques to develop new therapies for rare and cardiometabolic disorders.